CTA30X UCAR-T
/ Imviva Biotechnologies
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 29, 2022
UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | N=72 ➔ 0 | Recruiting ➔ Withdrawn
CAR T-Cell Therapy • Enrollment change • Trial withdrawal • Acute Lymphocytic Leukemia • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19
1 to 1
Of
1
Go to page
1